bf/NASDAQ:ONTX_icon.jpeg

NASDAQ:ONTX

Onconova Therapeutics, Inc.

  • Stock

USD

Last Close

1.00

02/04 20:00

Market Cap

20.90M

Beta: 1.77

Volume Today

1.25M

Avg: 588.32K

PE Ratio

−0.75

PFCF: −0.84

Preview

Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page

Subscribe NowHelp
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
average inventory
843.50K
-
1.63M
92.77%
782.50K
51.88%
48.50K
-
average payables
3.87M
-
3.72M
3.74%
4.37M
17.40%
5.75M
31.62%
5.11M
11.16%
4.16M
18.73%
4.55M
9.55%
3.79M
16.63%
3.31M
12.82%
2.81T
84,917,594.73%
average receivables
752K
-
767.50K
2.06%
45K
94.14%
47K
4.44%
66.50K
41.49%
67.50K
1.50%
32.50K
51.85%
28.50K
12.31%
9.00B
31,578,898.25%
book value per share
2.36K
-
990.50
58.10%
218.41
77.95%
-292.27
233.82%
19.59
106.70%
12.07
38.40%
0.53
95.59%
2.74
414.82%
1.35
50.59%
0.51
62.45%
capex per share
-23.69
-
-0.06
-
-0.00
97.75%
-0.00
-
capex to depreciation
-0.53
-
-3.93
-
-1.15
70.63%
-0.88
-
capex to operating cash flow
0.00
-
0.00
-
0.00
75.38%
0.00
-
capex to revenue
-0.28
-
-0.03
-
-0.06
157.73%
-0.06
-
cash per share
4.53K
-
1.96K
56.74%
1.09K
44.48%
100.60
90.75%
61.72
38.64%
23.70
61.61%
1.64
93.08%
3.27
99.52%
1.85
43.34%
0.99
46.48%
days of inventory on hand
days payables outstanding
days sales outstanding
47.92
-
2.04
95.74%
27.36
1,241.21%
10.40
61.98%
16.39
57.51%
58.46
256.79%
45.22
22.65%
46.84
3.57%
29.07
37.93%
debt to assets
0.12
-
0.16
30.23%
0.18
13.41%
0.23
-
debt to equity
0.25
-
0.37
46.58%
0.97
161.80%
0.77
-
dividend yield
earnings yield
-0.89
-
-1.10
22.88%
-1.96
78.17%
-1.78
8.82%
-2.36
32.48%
-3.93
66.39%
-0.31
92.18%
-0.37
19.90%
-1.35
265.17%
-1.21
10.09%
enterprise value
27.65M
-
2.03M
92.66%
-11.35M
659.20%
9.48M
183.48%
-8.27M
187.25%
-17.26M
108.75%
62.77M
463.69%
-12.15M
119.35%
-25.17M
107.17%
-5.17T
20,549,732.07%
enterprise value over ebitda
-0.43
-
-0.09
80.37%
0.41
581.66%
-0.35
184.37%
0.33
195.97%
0.79
138.65%
-2.53
419.33%
0.72
128.52%
1.28
77.51%
0.25
80.13%
ev to operating cash flow
-0.48
-
-0.06
86.45%
0.72
1,204.68%
-0.40
155.42%
0.36
191.57%
0.83
127.44%
-2.72
428.32%
0.62
122.92%
1.54
147.77%
0.29
81.33%
ev to sales
34.57
-
0.18
99.49%
-2.05
1,255.10%
12.04
688.29%
-6.73
155.92%
-7.91
17.43%
271.74
3,536.92%
-53.75
119.78%
-111.36
107.17%
-22.88
79.45%
free cash flow per share
-6.01K
-
-3.09K
48.61%
-803.75
74.00%
-595.49
25.91%
-82.55
86.14%
-21.78
73.62%
-1.99
90.86%
-1.16
41.83%
-0.78
32.69%
-0.86
9.72%
free cash flow yield
-0.81
-
-1.43
76.13%
-1.57
9.97%
-1.76
12.12%
-2.61
47.82%
-3.82
46.50%
-0.28
92.61%
-0.45
60.83%
-1.20
164.08%
-1.15
4.35%
graham net net
2.06K
-
906.94
56.07%
208.38
77.02%
-294.29
241.22%
16.22
105.51%
11.16
31.22%
0.45
95.95%
2.72
501.40%
1.33
51.21%
0.42
68.29%
graham number
18.76K
-
7.27K
61.24%
2.22K
69.52%
1.99K
10.21%
181.63
90.87%
78.03
57.04%
5.10
93.47%
7.61
49.42%
5.16
32.18%
3.21
37.77%
income quality
0.90
-
1.30
43.90%
0.80
38.17%
0.99
22.97%
1.11
12.47%
0.97
12.88%
0.92
5.32%
1.21
31.44%
0.86
28.74%
0.95
10.15%
intangibles to total assets
0
-
0
0
0
0
0
0
0
0
0
interest coverage
-31.87K
-
1.40K
-
interest debt per share
600.02
-
368.40
38.60%
212.67
42.27%
15.13
-
-0.00
-
inventory turnover
invested capital
0.25
-
0.37
46.58%
0.97
161.80%
0.77
-
market cap
71.23M
-
21.83M
69.36%
10.05M
53.97%
13.50M
34.35%
8.70M
35.54%
5.47M
37.18%
81.80M
1,396.43%
42.92M
47.53%
13.59M
68.34%
15.65T
115,149,937.24%
net current asset value
23.19M
-
10.58M
54.38%
4.96M
53.09%
-10.94M
320.37%
5.23M
147.81%
11.37M
117.52%
5.97M
47.49%
46.07M
671.34%
28.28M
38.61%
10.65T
37,650,161.63%
net debt to ebitda
0.68
-
0.83
21.50%
0.77
6.90%
0.15
81.00%
0.68
363.86%
1.04
53.10%
0.77
26.50%
3.27
326.61%
1.97
39.70%
1.03
48.05%
net income per share
-6.62K
-
-2.37K
64.15%
-999.64
57.87%
-602.28
39.75%
-74.83
87.58%
-22.42
70.03%
-2.17
90.33%
-0.94
56.63%
-0.88
6.92%
-0.90
3.14%
operating cash flow per share
-5.99K
-
-3.09K
48.40%
-803.75
74.00%
-595.49
25.91%
-82.55
86.14%
-21.72
73.69%
-1.99
90.84%
-1.16
41.79%
-0.78
32.69%
-0.85
9.63%
payables turnover
receivables turnover
7.62
-
178.90
2,248.73%
13.34
92.54%
35.09
163.03%
22.28
36.51%
6.24
71.97%
8.07
29.28%
7.79
3.45%
12.56
61.11%
research and ddevelopement to revenue
61.78
-
2.26
96.34%
3.62
60.11%
24.29
571.28%
13.78
43.27%
7.12
48.36%
73.15
927.80%
32.29
55.86%
50.47
56.31%
50.58
0.21%
return on tangible assets
-1.35
-
-1.02
23.97%
-0.85
17.23%
-4.84
471.61%
-1.15
76.28%
-0.91
20.87%
-1.26
38.58%
-0.29
77.33%
-0.46
62.92%
-0.84
79.71%
revenue per share
83.13
-
1.13K
1,263.56%
281.89
75.13%
19.67
93.02%
4.47
77.30%
2.28
49.03%
0.02
99.13%
0.01
32.56%
0.01
19.49%
0.01
0.38%
roe
-2.80
-
-2.40
14.43%
-4.58
91.06%
2.06
145.02%
-3.82
285.32%
-1.86
51.35%
-4.07
119.28%
-0.34
91.58%
-0.65
88.37%
-1.78
174.64%
roic
-2.24
-
-1.75
21.87%
-2.80
60.12%
2.20
178.75%
-2.42
210.05%
-1.88
22.62%
-4.05
115.82%
-0.35
91.35%
-0.67
91.02%
-1.90
184.27%
sales general and administrative to revenue
18.90
-
0.83
95.60%
1.65
98.87%
9.41
468.57%
6.18
34.35%
3.82
38.12%
36.04
842.87%
41.70
15.70%
37.38
10.38%
40.24
7.66%
shareholders equity per share
2.36K
-
990.50
58.10%
218.41
77.95%
-292.27
233.82%
19.59
106.70%
12.07
38.40%
0.53
95.59%
2.74
414.82%
1.35
50.59%
0.51
62.45%
stock based compensation to revenue
6.33
-
0.33
94.78%
0.71
114.37%
2.17
206.70%
0.93
57.01%
0.48
48.60%
1.60
232.74%
2.55
59.55%
5.19
103.47%
5.76
11.01%
tangible asset value
23.62M
-
10.84M
54.11%
5.13M
52.70%
-10.86M
311.84%
5.39M
149.60%
11.57M
114.85%
6.17M
46.65%
46.12M
646.88%
28.31M
38.62%
10.67T
37,698,158.50%
tangible book value per share
2.45K
-
1.07K
56.30%
260.60
75.70%
-271.52
204.19%
19.59
107.22%
12.07
38.40%
0.53
95.59%
2.74
414.82%
1.35
50.59%
0.51
62.45%
working capital
36.65M
-
15.58M
57.49%
12.91M
17.14%
-5.07M
139.30%
9.33M
283.86%
15.18M
62.77%
9.76M
35.69%
49.31M
405.12%
31.30M
36.53%
13.44T
42,937,825.31%

All numbers in USD (except ratios and percentages)